Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial

Abstract Background Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. This study aims to assess a 1:20 delta-9-tetrahydrocannabinol/canna...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Taylan Gurgenci, Janet Hardy, Georgie Huggett, Karyn Foster, Anita Pelecanos, Ristan Greer, Jennifer Philip, Alison Haywood, Ruwani Mendis, Patsy Yates, Phillip Good
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2024-05-01
Serier:	Trials
Online adgang:	https://doi.org/10.1186/s13063-024-08091-z
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!